Market Access
Learning to Speak HEOR
As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma ...
Healthcare Midterm Election Results: A Marketing Toss Up
With the 2018 midterm elections in the rearview mirror, the business of healthcare continues ...
California Will Require Pharma to Explain Rationale Behind Price Hikes in 2019
As President Trump continues to make promises to lower drug prices, the state of ...
Preparing for Possible Changes to Medicare Part D
Even prior to the midterm elections, the Trump administration has been proposing several changes ...
Is Step Therapy Now a Possibility for Part B Drugs?
The Trump administration’s drug cost blueprint looked at the possibility of moving Part B ...
Seize the Day
The multiple forces dramatically reshaping the healthcare industry show no sign of abating. Influence ...
Breaking Opioid Addiction
Despite growing awareness of the dangers around opioid overuse, 30% of all people in ...
The Impact of Express Scripts’ 2019 Formulary Exclusion List
Earlier this month, Express Scripts announced its 2019 National Preferred Formulary (NPF), which added ...
Will Trump’s Blueprint for Lower Drug Prices Change the Price Negotiation Process?
Last month, the Trump administration once again made its desire to lower drug prices ...
Prescription Pushback
In value-based healthcare, health plans/PBMs, employers, and government-sponsored healthcare programs focus on optimizing patient ...
Creating Value in Bundled Payments
A debate has been brewing over the past few years surrounding the Center for ...
The Payer Landscape is Evolving—But Change is Slow
Payers are evolving. Just look at the recent deals that blend together some combination ...
Beyond Price Negotiation—What Really Matters to Payers
We’ve all heard the adage “cost is what you pay, value is what you ...
